help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by SEERSHOLM, N.
Right arrow Articles by DIRKSEN, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by SEERSHOLM, N.
Right arrow Articles by DIRKSEN, A.

Am. J. Respir. Crit. Care Med., Volume 161, Number 1, January 2000, 81-84

Risk of Hospital Admission for Obstructive Pulmonary Disease in alpha 1-Antitrypsin Heterozygotes of Phenotype PiMZ

NIELS SEERSHOLM, JON TORGNY ROSTRUP WILCKE, AXEL KOK-JENSEN, and ASGER DIRKSEN

Respiratory Department Y, Gentofte Hospital, Hellerup; and Respiratory Clinic, Rigshospitalet, Copenhagen, Denmark

Whether subjects heterozygous for alpha 1-antitrypsin (alpha 1-AT) deficiency are at risk for development of obstructive pulmonary disease (OPD) has been discussed for the past three decades. Both cohort and case-control studies have reached different conclusions, with the major problems being small sample sizes. A cohort of heterozygotes with the phenotype PiMZ was retrieved from the Danish Alpha1-Antitrypsin Deficiency Registry. Ten matched controls for each PiMZ subject were identified from the files of the Danish Central Population Registry. Cases and controls were subsequently linked to the files of the Danish Hospital Discharge Registry, and relative risk for OPD was calculated. In the cohort of 1,551 PiMZ subjects (11,678 person-years), we identified 47 subjects with a discharge diagnosis of OPD, as compared with 206 subjects with this diagnosis in the control group (109,748 person-years), yielding a relative risk (RR) of 2.2 (95% confidence interval [CI]: 1.5 to 3.0). This increased risk was present in both men and women and in all age groups; however, it was significant only in the age group from 40 to 79 yr. Of the 1,551 PiMZ subjects, 565 (36%) were first-degree relatives of PiZ index cases, and it appeared that only this group was at increased risk of hospital admission for OPD (RR: 3.4, 95% CI: 2.2 to 5.3). We conclude that alpha 1-AT heterozygotes of phenotype PiMZ are at increased risk of hospital admission for OPD if they are first-degree relatives of PiZ index cases only, and that other, yet unknown genetic or environmental factors contribute to the development of lung disease. Seersholm N, Wilcke JTR, Kok-Jensen A, Dirksen A. Risk of hospital admission for obstructive pulmonary disease in alpha 1-antitrypsin heterozygotes of phenotype PiMZ.




This article has been cited by other articles:


Home page
 Proc Am Thorac SocHome page
C. P. Hersh, D. L. DeMeo, and E. K. Silverman
National Emphysema Treatment Trial State of the Art: Genetics of Emphysema
Proceedings of the ATS, May 1, 2008; 5(4): 486 - 493.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
G. E. Silva, S. Guerra, S. Keim, R. A. Barbee, and D. L. Sherrill
Longitudinal Decline of Diffusing Capacity of the Lung for Carbon Monoxide in Community Subjects With the PiMZ {alpha}1-Antitrypsin Phenotype
Chest, May 1, 2008; 133(5): 1095 - 1100.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. Dahl, J. Vestbo, P. Lange, S. E. Bojesen, A. Tybjaerg-Hansen, and B. G. Nordestgaard
C-reactive Protein As a Predictor of Prognosis in Chronic Obstructive Pulmonary Disease
Am. J. Respir. Crit. Care Med., February 1, 2007; 175(3): 250 - 255.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
O. Senn, E. W. Russi, M. Imboden, and N. M. Probst-Hensch
{alpha}1-Antitrypsin deficiency and lung disease: risk modification by occupational and environmental inhalants
Eur. Respir. J., November 1, 2005; 26(5): 909 - 917.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
M. Dahl, C. P. Hersh, N. P. Ly, C. S. Berkey, E. K. Silverman, and B. G. Nordestgaard
The protease inhibitor PI*S allele and COPD: a meta-analysis
Eur. Respir. J., July 1, 2005; 26(1): 67 - 76.
[Abstract] [Full Text] [PDF]

Home page
 J. Med. Genet.Home page
I Ferrarotti, J Baccheschi, M Zorzetto, C Tinelli, L Corda, B Balbi, I Campo, E Pozzi, G Faa, P Coni, et al.
Prevalence and phenotype of subjects carrying rare variants in the Italian registry for alpha1-antitrypsin deficiency
J. Med. Genet., March 1, 2005; 42(3): 282 - 287.
[Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
M. E. J. Wadsworth, L. E. Vinall, A. L. Jones, R. J. Hardy, D. B. Whitehouse, S. L. Butterworth, W. S. Hilder, J. U. Lovegrove, and D. M. Swallow
Alpha1-Antitrypsin as a Risk for Infant and Adult Respiratory Outcomes in a National Birth Cohort
Am. J. Respir. Cell Mol. Biol., November 1, 2004; 31(5): 559 - 564.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
N Seersholm
Pi MZ and COPD: will we ever know?
Thorax, October 1, 2004; 59(10): 823 - 825.
[Full Text] [PDF]

Home page
 ThoraxHome page
C P Hersh, M Dahl, N P Ly, C S Berkey, B G Nordestgaard, and E K Silverman
Chronic obstructive pulmonary disease in {alpha}1-antitrypsin PI MZ heterozygotes: a meta-analysis
Thorax, October 1, 2004; 59(10): 843 - 849.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
D L DeMeo and E K Silverman
{alpha}1-Antitrypsin deficiency {middle dot} 2: Genetic aspects of {alpha}1-antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk
Thorax, March 1, 2004; 59(3): 259 - 264.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
American Thoracic Society/European Respiratory Society Statement: Standards for the Diagnosis and Management of Individuals with Alpha-1 Antitrypsin Deficiency
Am. J. Respir. Crit. Care Med., October 1, 2003; 168(7): 818 - 900.
[Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
D. D. Frangolias, J. Ruan, P. J. Wilcox, A. G. F. Davidson, L. T. K. Wong, Y. Berthiaume, R. Hennessey, A. Freitag, L. Pedder, M. Corey, et al.
{alpha}1-Antitrypsin Deficiency Alleles in Cystic Fibrosis Lung Disease
Am. J. Respir. Cell Mol. Biol., September 1, 2003; 29(3): 390 - 396.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
G M Corbo, F Forastiere, N Agabiti, V Dell'Orco, R Pistelli, G Massi, C A Perucci, and S Valente
Passive smoking and lung function in {alpha}1-antitrypsin heterozygote schoolchildren
Thorax, March 1, 2003; 58(3): 237 - 241.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
A J Sandford and E K Silverman
Chronic obstructive pulmonary disease * 1: Susceptibility factors for COPD the genotype-environment interaction
Thorax, August 1, 2002; 57(8): 736 - 741.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
M. Dahl, A. Tybjaerg-Hansen, P. Lange, J. Vestbo, and B. G. Nordestgaard
Change in Lung Function and Morbidity from Chronic Obstructive Pulmonary Disease in {alpha}1-Antitrypsin MZ Heterozygotes: A Longitudinal Study of the General Population
Ann Intern Med, February 19, 2002; 136(4): 270 - 279.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. J. TOBIN
Chronic Obstructive Pulmonary Disease, Pollution, Pulmonary Vascular Disease, Transplantation, Pleural Disease, and Lung Cancer in AJRCCM 2000
Am. J. Respir. Crit. Care Med., November 15, 2001; 164(10): 1789 - 1804.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
J.M. Anto, P. Vermeire, J. Vestbo, and J. Sunyer
Epidemiology of chronic obstructive pulmonary disease
Eur. Respir. J., May 1, 2001; 17(5): 982 - 994.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2000 American Thoracic Society 		  Solid Organ Transplant for the Intensivist 2008